Addi. Archivo Digital para la Docencia y la Investigación
Publicación
Artículo científico (JournalArticle)
Turning universal O into rare Bombay type blood
Red blood cell antigens play critical roles in blood transfusion since donor incompatibilities can be lethal. Recipients with the rare total deficiency in H antigen, the Oh Bombay phenotype, can only be transfused with group Oh blood to avoid serious transfusion reactions. We discover FucOB from the mucin-degrading bacteria Akkermansia muciniphila as a novel α-1,2-fucosidase able to hydrolyze Type I, Type II, Type III and Type V H antigens to obtain the afucosylated Bombay phenotype in vitro. We provide high-resolution X-ray crystal structures of FucOB, which show a three-domain architecture, including a GH95 glycoside hydrolase. In combination with site-directed mutagenesis, enzymatic activity and computational methods we unveil the molecular basis of substrate specificity and catalysis. Furthermore, using agglutination tests and flow cytometry-based techniques, we demonstrate the ability of FucOB to convert universal O type into rare Bombay type blood, providing exciting possibilities to facilitate transfusion in recipients/patients with Bombay phenotype., This work was supported by the MINECO/FEDER EU contract PID2019-105649RB-I00 and Severo Ochoa Excellence Accreditation SEV-2016-0644; the Basque Government contracts KK-2021-00034 and KK-2022/00107 and NIH R01AI149297 (to M.E.G.); EU Marie-Sklodowska Curie ITN, DIRNANO, contract 956544 and the Mizutani Foundation for Glycoscience contract 220115 (to F.C.). This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 844905 and “Ramón y Cajal” fellow from the Spanish Ministry of Economy and Competitiveness (B.T.) and the Basque Government (I.A.). We acknowledge Diamond Light Source (proposals mx28360), ALBA synchrotron beamline BL13-XALOC (mx2020094584), beamline X06DA at SLS (Villigen Switzerland; proposal 20201980), and iNEXT (proposals 1618/2538) for providing access to synchrotron radiation facilities.
Proyecto:
EC / H2020 220115
,
EC / H2020 844905